Physician profile
Patrick M Esposito
NPI 1326197971
$2,297.97
in general payments reported to CMS, 2019-2025
28 companies · $392 in 2025
The $392 reported for 2025 was more than what 90% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $111 · 2021: $282 · 2022: $301 · 2023: $646 · 2024: $371 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,408.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $344.12 | 2021-2024 | |
| Sanofi Pasteur INC. | $261.82 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $255.98 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Glaxosmithkline, LLC. | $239.39 | 2019-2025 | Bexsero, Pediarix, Rotarix |
| Sanofi-Aventis U.S. LLC | $188.80 | 2024-2025 | |
| Ironshore Pharmaceuticals INC. | $143.27 | 2019-2024 | |
| Cranial Technologies, INC | $91.28 | 2020-2024 | Doc Band |
| Tris Pharma INC | $85.96 | 2020-2022 | |
| Corium, LLC | $84.41 | 2022-2024 | Azstarys |
| Mirum Pharmaceuticals, INC. | $68.00 | 2023-2025 | Livmarli |
| Seqirus USA INC | $66.19 | 2023 | Flucelvax Quadrivalent |
| Alexion Pharmaceuticals, INC. | $65.24 | 2019-2025 | Koselugo |
| Verrica Pharmaceuticals INC. | $47.08 | 2024-2025 | Ycanth |
| Kaleo, INC. | $46.23 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.17 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $42.30 | 2019 | |
| Pfizer INC. | $28.54 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $23.95 | 2023 | Flumist Quadrivalent |
| Acadia Pharmaceuticals INC | $23.58 | 2024 | Daybue |
| Amneal Pharmaceuticals LLC | $21.66 | 2019 | |
| Collegium Pharmaceutical, INC. | $20.95 | 2025 | Jornay Pm |
| Phadia US INC. | $18.31 | 2021 | |
| Nestle Healthcare Nutrition INC. | $15.21 | 2023 | |
| Dermira, INC. | $15.03 | 2020 | |
| Noven Therapeutics, LLC | $14.84 | 2024 | Xelstrym |
| Supernus Pharmaceuticals, INC. | $14.54 | 2023 | Qelbree |
| Vertical Pharmaceuticals, LLC | $14.48 | 2024 | Relexxii |
| Adlon Therapeutics L.P. | $11.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Esposito listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.